JANUVIA

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

Retrieved on: 
Tuesday, March 7, 2023
Royal, National academy, DNA, Alvan, Harvard Medical School, Science, Merck, Dana–Farber Cancer Institute, JANUVIA, Chromosome, Roivant Sciences, DNA repair, Institute of technology, Cell, Therapy, Technical University of Munich, Schering-Plough, Drug discovery, Human Proteome Organization, Proteomics, University, Research, Analytical and Bioanalytical Chemistry, Radiation therapy, UCB, FRSC, Cancer, Royal Society, SAB, Susan, AbbVie, United States Air Force Scientific Advisory Board, Patient, GSK, National Academy of Medicine, British Mass Spectrometry Society, The German, Pharmaceutical industry, Chemistry, Medicine

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).
  • Covant uses its unprecedented high-throughput chemoproteomics platform to discover novel small molecule therapeutics against hard-to-drug immunology and oncology targets.
  • “This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs,” said Dr. Ivan Cornella, Chief Scientific Officer of Covant.
  • “I am thrilled to welcome our new Scientific Advisory Board members.

U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, Health, White House, Federal Government, Pharmaceutical, Public Policy, Government, MSD, YouTube, Mylan, United States Court of Appeals for the Federal Circuit, COVID-19, Twitter, NYSE, Douglas v. U.S. District Court ex rel Talk America, LinkedIn, Merck & Co., News, Review, Metformin, Electric Bond and Share Company v. Securities and Exchange Commission, Instagram, Vaccine, Coronavirus, Patent, Private Securities Litigation Reform Act, XR, Research, 1836 U.S. Patent Office fire, District court, Security (finance), MRK, JANUVIA, SEC, United States District Court for the Southern District of Alabama, Animal, List, United States patent law, Online gambling, Pharmaceutical industry, Viatris, Facebook, Merck

Viatris had challenged validity of U.S. Patent No.7,326,708 in an inter partes review before the U.S. Patent Office.

Key Points: 
  • Viatris had challenged validity of U.S. Patent No.7,326,708 in an inter partes review before the U.S. Patent Office.
  • On May 7, 2021, the Patent Office issued a decision in Mercks favor, finding all challenged claims valid.
  • Viatris appealed that decision to the Court of Appeals for the Federal Circuit, which today affirmed the decision.
  • Viatris had previously challenged validity of the patent in a case filed in the U.S. District Court for the Northern District of West Virginia.

U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit

Retrieved on: 
Thursday, September 22, 2022
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Infectious Diseases, Clinical Trials, MSD, YouTube, United States Court of Appeals for the Federal Circuit, COVID-19, Twitter, NYSE, Review, Food, Douglas v. U.S. District Court ex rel Talk America, U.S. Patent No. 1, LinkedIn, Merck & Co., News, Metformin, U.S. Securities and Exchange Commission, Williams & Connolly, Connolly, Instagram, Vaccine, Coronavirus, Patent, Private Securities Litigation Reform Act, Court, Research, 1836 U.S. Patent Office fire, District court, Security (finance), MRK, SEC, Animal, Food and Drug Administration, Generic drug, Pharmaceutical industry, Viatris, Facebook, JANUVIA, Merck

The Court found that both Merck patents at issue were valid and infringed.

Key Points: 
  • The Court found that both Merck patents at issue were valid and infringed.
  • 7,326,708, covers the dihydrogen phosphate salt of sitagliptin and is set to expire on Nov. 24, 2026, with pediatric exclusivity extending to May 24, 2027.
  • Merck had filed infringement actions against Viatris under both patents, for which Viatris alleged non-infringement and/or invalidity.
  • On May 7, 2021, the Patent Office issued a decision in Mercks favor, finding all challenged claims valid.